Allarity Therapeutics (ALLR) Expects Q4 EPS of $0.01–$0.04
Allarity Therapeutics (ALLR) reported $24.1M in cash at Q3's end and expects Q4 EPS of $0.01–$0.04, primarily due to a legacy liability settlement gain, according to the company.
How this was made

The 30-second read
Why it matters
The guidance provides the first forward EPS estimate for Q4, setting market expectations.
Market read
New guidance may influence Allarity's stock price ahead of the upcoming quarter.
What to watch
Potential upcoming clinical data on stenoparib could offset modest EPS guidance.
Background
Allarity Therapeutics reported Q3 cash position and issued Q4 EPS guidance based on a liability settlement.
Ticker impact
Allarity Therapeutics provided Q4 EPS guidance of $0.01–$0.04, a new forward-looking figure not previously disclosed.
likely modest downside as investors price in low EPS guidance
The EPS range is low for a biotech and is driven by a one‑time liability settlement, offering limited upside.
Market effects
May temper sentiment toward early‑stage biotech earnings guidance.
Limited to US biotech investors.
Low, confined to Allarity shareholders.
Counterpoint
The liability settlement could be a catalyst if cash improves balance sheet, offering upside.
Key entities
- companyAllarity Therapeutics
Early‑stage clinical biotech issuing Q4 EPS guidance.